185 related articles for article (PubMed ID: 33416178)
21. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
[TBL] [Abstract][Full Text] [Related]
22. FOXM1-induced upregulation of lncRNA OR3A4 promotes the progression of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
Meng H; Zhao B; Wang Y
Exp Mol Pathol; 2020 Aug; 115():104451. PubMed ID: 32417392
[TBL] [Abstract][Full Text] [Related]
23. CDK6 overexpression resulted from microRNA‑320d downregulation promotes cell proliferation in diffuse large B‑cell lymphoma.
Su H; Chang J; Xu M; Sun R; Wang J
Oncol Rep; 2019 Jul; 42(1):321-327. PubMed ID: 31059102
[TBL] [Abstract][Full Text] [Related]
24. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Sun JR; Zhang X; Zhang Y
Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419
[TBL] [Abstract][Full Text] [Related]
25. miR‑101 regulates the cell proliferation and apoptosis in diffuse large B‑cell lymphoma by targeting MEK1 via regulation of the ERK/MAPK signaling pathway.
Huang Y; Zou Y; Lin L; Ma X; Zheng R
Oncol Rep; 2019 Jan; 41(1):377-386. PubMed ID: 30365139
[TBL] [Abstract][Full Text] [Related]
26. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
27. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma.
Yousefi Z; Sharifzadeh S; Zare F; Eskandari N
Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389
[TBL] [Abstract][Full Text] [Related]
28. Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma.
Ge X; Lv X; Feng L; Liu X; Gao J; Chen N; Wang X
PLoS One; 2012; 7(6):e39449. PubMed ID: 22768080
[TBL] [Abstract][Full Text] [Related]
29. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
30. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
Yang JM; Jang JY; Jeon YK; Paik JH
J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
[TBL] [Abstract][Full Text] [Related]
32. lncRNA SNHG14 promotes oncogenesis and immune evasion in diffuse large-B-cell lymphoma by sequestering miR-152-3p.
Tian Y; Li L; Lin G; Wang Y; Wang L; Zhao Q; Hu Y; Yong H; Wan Y; Zhang Y
Leuk Lymphoma; 2021 Jul; 62(7):1574-1584. PubMed ID: 33682607
[TBL] [Abstract][Full Text] [Related]
33. ASPM Predicts Poor Clinical Outcome and Promotes Tumorigenesis for Diffuse Large B-cell Lymphoma.
Wu J; He Z; Zhu Y; Jiang C; Deng Y; Wei B
Curr Cancer Drug Targets; 2021; 21(1):80-89. PubMed ID: 32933462
[TBL] [Abstract][Full Text] [Related]
34. Eukaryotic initiation factor 3a promotes the development of diffuse large B-cell lymphoma through regulating cell proliferation.
Sun H; Shang J; Liu X; Ren S; Hu S; Wang X
BMC Cancer; 2024 Apr; 24(1):432. PubMed ID: 38589831
[TBL] [Abstract][Full Text] [Related]
35. Effects of microRNA-21 on apoptosis by regulating the expression of PTEN in diffuse large B-cell lymphoma.
Song J; Shao Q; Li C; Liu H; Li J; Wang Y; Song W; Li L; Wang G; Shao Z; Fu R
Medicine (Baltimore); 2017 Sep; 96(39):e7952. PubMed ID: 28953617
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
38. Long Non-Coding RNA Paternally Expressed Imprinted Gene 10 (PEG10) Elevates Diffuse Large B-Cell Lymphoma Progression by Regulating Kinesin Family Member 2A (KIF2A) via Targeting MiR-101-3p.
Zhao J; Su L; Jiang J
Med Sci Monit; 2020 Sep; 26():e922810. PubMed ID: 32976381
[TBL] [Abstract][Full Text] [Related]
39. TIMD4 exhibits regulatory capability on the proliferation and apoptosis of diffuse large B-cell lymphoma cells via the Wnt/β-catenin pathway.
Li Y; Zhang PY; Yang ZW; Ma F; Li FX
J Gene Med; 2020 Aug; 22(8):e3186. PubMed ID: 32187802
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
